Lates News

According to Every AI News, Open Source Securities released a research report on May 18, giving a buy rating to Noucord Genhuah (688428.SH). The rating reasons mainly include: 1) The strong growth in sales of the core single product Aoputinib, raising the annual sales guidance to 35%; 2) Building a product matrix in the field of hematologic malignancies with Aoputinib as the core; 3) Deeply cultivating the self-immunity blue ocean market, actively exploring international cooperation and external authorization for important pipelines. (Daily Economic News)